Goodwin Procter attorneys recently advised GreenOak Real Estate Advisors in connection with a joint venture with Synergy Investments to acquire 10 Post Office Square, a historic 13-story office building in Boston’s financial district, for $143 million. The building has 445,000 square feet of office space. Terms of the transaction were not disclosed. More >>

Goodwin Procter recently advised Paramount Group Inc. in connection with its initial public offering of 131 million shares of common stock. Shares priced at $17.50 per share, making the offering the largest IPO in the REIT industry since it was first established 50 years ago. The company is listed on the New York Stock Exchange and shares began trading on November 19, 2014 under the ticker “PGRE.” More >>

Goodwin Procter recently advised Hampden Bancorp, Inc. in connection with the signing of a definitive agreement pursuant to which Berkshire Hills Bancorp, Inc. will acquire Hampden. The transaction, valued at approximately $109 million, is expected to close in the second quarter of 2015. Under the terms of the merger agreement, shares of Hampden common stock will be exchanged for .81 shares of Berkshire Hills common stock. Berkshire Hill’s total assets will increase to $7.1 billion, including $706 million of assets acquired from Hampden Bank. More >>

International law firm McDermott Will & Emery LLP represented Constellation Brands, Inc., a leading beverage alcohol company, in its concurrent issuances on November 3, 2014 of $400 million aggregate principal amount of Senior Notes due 2019 and $400 million aggregate principal amount of Senior Notes due 2024 in a public offering under a shelf registration statement filed with the Securities and Exchange Commission. More >>

Goodwin attorneys recently advised F-star Alpha Ltd in connection with its exclusive option agreement with Bristol-Myers Squibb. Bristol-Myers Squibb has purchased an exclusive option to acquire F-Star Alpha and thereby gain worldwide rights to FS102, a Human Epidermal growth factor Receptor 2 (HER-2)-targeted therapy. Under the terms of the agreement, Bristol-Myers Squibb will make payments aggregating to $50 million that consist of an option fee for the right to acquire F-star Alpha, payment for certain rights and licenses from F-star Alpha and a clinical milestone payment upon initiation of the Phase 1 trial. Total aggregate consideration may reach $475 million. Additional details regarding the transaction are available in BMS’s press release. More >>

Ropes & Gray represented CRC Health Group Inc. in its planned $1.175 billion acquisition by Acadia Healthcare announced Oct. 29. CRC is a California-based substance abuse treatment provider operating 120 facilities dedicated to the service of approximately 40,000 patients each day. The deal is scheduled to be completed in the first quarter of 2015. More >>

Goodwin attorneys recently advised Canaan Partners on its tenth fund, Canaan X, which raised $675 million of capital. The fund is reportedly the eighth largest venture capital fund raised in the United States in 2014, according to the National Venture Capital Association and Thomson Reuters, and will focus on early stage and seed stage investments. More >>

Goodwin attorneys recently advised marketing and sales software company, HubSpot, on its initial public offering of 5,000,000 common shares. Shares priced at $25 per share and trading began on October 9 on the New York Stock Exchange under ticker “HUBS.” More >>